Medicus Pharma to acquire Antev for $73m.

Medicus Pharma, a biotech company focused on accelerating the clinical development of novel therapeutics, agreed to acquire Antev, a UK-based clinical-stage company developing Teverelix, a next generation GnRH antagonist, for $73m. The acquisition provides Medicus with Antev's lead asset, Teverelix, which is being developed as a first-in-class treatment for preventing the recurrence of acute urinary retention in patients with an enlarged prostate and as a hormone therapy for advanced prostate cancer patients with increased cardiovascular risk.